Crystal Adam, President of R&D at Tango Therapeutics ($TNGX), sold shares on the open market four times in the last year, totaling $1.22 million. Her most recent sale occurred on March 5, 2026. These transactions rank her 4,473rd among 11,678 insiders by sale value, below the average of $8.6 million per insider and 6.4 transactions. She made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | M | Common Stock | 27000 | $5.20 | 139,622.0000 | 134,593,998 | 23.97% | 0.02% |
| April 1, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 27000 | $21.20 | 112,622.0000 | 134,593,998 | 19.34% | 0.02% |
| April 1, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | M | Stock Option (Right to Buy) | 27000 | $0.00 | 433,500.0000 | 134,593,998 | 5.86% | 0.02% |
| March 25, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | M | Stock Option (Right to Buy) | 12000 | $0.00 | 460,500.0000 | 134,593,998 | 2.54% | 0.01% |
| March 25, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 12000 | $20.11 | 112,622.0000 | 134,593,998 | 9.63% | 0.01% |
| March 25, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | M | Common Stock | 12000 | $5.20 | 124,622.0000 | 134,593,998 | 10.66% | 0.01% |
| March 5, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 20251 | $15.00 | 112,622.0000 | 134,593,998 | 15.24% | 0.02% |
| Feb. 25, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 54345 | $12.77 | 132,873.0000 | 134,593,998 | 29.03% | 0.04% |
| Feb. 3, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 201 | $12.90 | 187,218.0000 | 134,593,998 | 0.11% | 0.00% |
| Feb. 2, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | A | Common Stock | 47460 | $0.00 | 205,670.0000 | 134,593,998 | 30.00% | 0.04% |
| Feb. 3, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | S | Common Stock | 18251 | $12.26 | 187,419.0000 | 134,593,998 | 8.87% | 0.01% |
| Feb. 2, 2026 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | President, R&D | A | Stock Option (Right to Buy) | 284760 | $0.00 | 284,760.0000 | 134,593,998 | 9999.99% | 0.21% |
| Feb. 4, 2025 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | S | Common Stock | 7432 | $2.99 | 165,061.0000 | 0 | 4.31% | 0.00% |
| Feb. 5, 2025 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | S | Common Stock | 6851 | $3.16 | 158,210.0000 | 0 | 4.15% | 0.00% |
| Feb. 3, 2025 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | A | Stock Option (Right to Buy) | 318090 | $0.00 | 318,090.0000 | 0 | 9999.99% | 0.00% |
| Feb. 3, 2025 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | A | Common Stock | 53015 | $0.00 | 172,493.0000 | 0 | 44.37% | 0.00% |
| Feb. 7, 2024 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | S | Common Stock | 4083 | $12.62 | 119,478.0000 | 0 | 3.30% | 0.00% |
| Feb. 6, 2024 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | S | Common Stock | 4288 | $12.56 | 123,561.0000 | 0 | 3.35% | 0.00% |
| Feb. 1, 2024 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | A | Common Stock | 46599 | $0.00 | 46,599.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Tango Therapeutics, Inc. | $TNGX | Crystal Adam | See Remarks | A | Stock Option (Right to Buy) | 279593 | $0.00 | 279,593.0000 | 0 | 9999.99% | 0.00% |